Publication: The impact of the COVID-19 pandemic on antimicrobial usage: An international patient-level cohort study
Loading...
Program
Organization Authors
Co-Authors
Farzana, Refath
Harbarth, Stephan Jurgen
Yu, Ly-Mee
Carretto, Edoardo
Moore, Catrin E.
Feasey, Nicholas Alexander
Gales, Ana C.
Galal, Ushma
Yong, Dongeun
Yusuf, Md Abdullah
Date
Language
Type
Embargo Status
Yes
Journal Title
Journal ISSN
Volume Title
Alternative Title
Abstract
Background: This study aimed to evaluate the trends in antimicrobial prescription during the first 1.5 years of COVID-19 pandemic. Methods: This was an observational, retrospective cohort study using patient-level data from Bangladesh, Brazil, India, Italy, Malawi, Nigeria, South Korea, Switzerland and Turkey from patients with pneumonia and/or acute respiratory distress syndrome and/or sepsis, regardless of COVID-19 positivity, who were admitted to critical care units or COVID-19 specialized wards. The changes of antimicrobial prescription between pre-pandemic and pandemic were estimated using logistic or linear regression. Pandemic effects on month-wise antimicrobial usage were evaluated using interrupted time series analyses (ITSAs). Results: Antimicrobials for which prescriptions significantly increased during the pandemic were as follows: meropenem in Bangladesh (95% CI: 1.94-4.07) with increased prescribed daily dose (PDD) (95% CI: 1.17-1.58) and Turkey (95% CI: 1.09-1.58), moxifloxacin in Bangladesh (95% CI: 4.11-11.87) with increased days of therapy (DOT) (95% CI: 1.14-2.56), piperacillin/tazobactam in Italy (95% CI: 1.07-1.48) with increased DOT (95% CI: 1.01-1.25) and PDD (95% CI: 1.05-1.21) and azithromycin in Bangladesh (95% CI: 3.36-21.77) and Brazil (95% CI: 2.33-8.42). ITSA showed a significant drop in azithromycin usage in India (95% CI: -8.38 to -3.49â€...g/100 patients) and South Korea (95% CI: -2.83 to -1.89 g/100 patients) after WHO guidelines v1 release and increased meropenem usage (95% CI: 93.40-126.48 g/100 patients) and moxifloxacin (95% CI: 5.40-13.98 g/100 patients) in Bangladesh and sulfamethoxazole/trimethoprim in India (95% CI: 0.92-9.32 g/100 patients) following the Delta variant emergence. Conclusions: This study reinforces the importance of developing antimicrobial stewardship in the clinical settings during inter-pandemic periods. © 2025 The Author(s).
Source
Publisher
Oxford University Press
Citation
item.page.haspartof
Source
JAC-Antimicrobial resistance
item.page.ispartofseries
item.page.edition
DOI
10.1093/jacamr/dlaf037
item.page.datauri
item.page.link
Rights
CC BY (Attribution)
Copyrights Note
Creative Commons license
Except where otherwise noted, this item's license is described as CC BY (Attribution)

